Tumor Lipids of Pediatric Papillary Renal Cell Carcinoma Stimulate Unconventional T Cells.
Adolescent
Antigens, CD1d
/ metabolism
Carcinoma, Renal Cell
/ immunology
Case-Control Studies
Cell Proliferation
Cells, Cultured
Child
Child, Preschool
Humans
Infant
Kidney Neoplasms
/ immunology
Lipid Metabolism
Lymphocyte Activation
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Paracrine Communication
Phenotype
Signal Transduction
T-Lymphocytes
/ immunology
Tumor Microenvironment
CD1d
TILs
lipid antigens
pediatric papillary renal cell carcinoma
unconventional T cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
31
01
2020
accepted:
07
07
2020
entrez:
25
9
2020
pubmed:
26
9
2020
medline:
20
4
2021
Statut:
epublish
Résumé
Papillary renal cell carcinoma (PRCC) is a rare entity in children with no established therapy protocols for advanced diseases. Immunotherapy is emerging as an important therapeutic tool for childhood cancer. Tumor cells can be recognized and killed by conventional and unconventional T cells. Unconventional T cells are able to recognize lipid antigens presented via CD1 molecules independently from major histocompatibility complex, which offers new alternatives for cancer immunotherapies. The nature of those lipids is largely unknown and α-galactosylceramide is currently used as a synthetic model antigen. In this work, we analyzed infiltrating lymphocytes of two pediatric PRCCs using flow cytometry, immunohistochemistry and qRT-PCR. Moreover, we analyzed the CD1d expression within both tumors. Tumor lipids of PRCC samples and three normal kidney samples were fractionated and the recognition of tumor own lipid fractions by unconventional T cells was analyzed in an
Identifiants
pubmed: 32973759
doi: 10.3389/fimmu.2020.01819
pmc: PMC7468390
doi:
Substances chimiques
Antigens, CD1d
0
CD1D protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1819Informations de copyright
Copyright © 2020 Lehmann, Paret, El Malki, Russo, Neu, Wingerter, Seidmann, Foersch, Ziegler, Roth, Backes, Sandhoff and Faber.
Références
Virchows Arch. 2018 May;472(5):815-824
pubmed: 29445891
Immunol Lett. 1996 Oct;53(1):15-8
pubmed: 8946212
Nat Immunol. 2012 Sep;13(9):851-6
pubmed: 22820602
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Sep;1865(9):158741
pubmed: 32474112
J Clin Pathol. 2015 Mar;68(3):200-5
pubmed: 25477528
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Nat Immunol. 2015 Nov;16(11):1114-23
pubmed: 26482978
PLoS Biol. 2019 Mar 1;17(3):e3000169
pubmed: 30822302
J Immunol. 2004 Sep 15;173(6):3693-706
pubmed: 15356115
Arch Pharm Res. 2019 Jul;42(7):543-548
pubmed: 30859410
Cell Immunol. 2015 Jul;296(1):31-40
pubmed: 25991474
N Engl J Med. 2005 Dec 8;353(23):2477-90
pubmed: 16339096
Transl Oncol. 2014 Aug;7(4):484-92
pubmed: 24969538
J Exp Med. 2005 May 2;201(9):1503-17
pubmed: 15867097
Nat Immunol. 2012 Sep;13(9):857-63
pubmed: 22820603
Surg Pathol Clin. 2010 Sep 1;3(3):641-651
pubmed: 21057600
Semin Cell Dev Biol. 2001 Apr;12(2):139-48
pubmed: 11292380
Nat Immunol. 2013 Nov;14(11):1137-45
pubmed: 24076636
Clin Cancer Res. 2015 Jul 1;21(13):3031-40
pubmed: 25688160
Clin Cancer Res. 2013 Aug 1;19(15):4079-91
pubmed: 23785047
Oncoimmunology. 2015 Feb 03;4(1):e985082
pubmed: 25949868
Pediatr Blood Cancer. 2019 Aug;66(8):e27766
pubmed: 31012542
Cancer. 2006 Dec 15;107(12):2906-14
pubmed: 17109448
Cancer. 2004 Oct 1;101(7):1575-83
pubmed: 15378495
PLoS One. 2009 Jun 17;4(6):e5926
pubmed: 19536290
Cell Mol Immunol. 2017 Mar;14(3):245-253
pubmed: 27890919
J Biol Chem. 2007 Feb 2;282(5):3083-94
pubmed: 17145749
Pediatr Surg Int. 2018 Feb;34(2):195-201
pubmed: 29018959
J Virol. 2008 Feb;82(3):1155-65
pubmed: 18045946
Blood. 2004 Jan 15;103(2):383-9
pubmed: 14512316
J Immunol. 2013 Jul 1;191(1):30-4
pubmed: 23740951
Int J Surg Pathol. 2011 Apr;19(2):170-9
pubmed: 20034980
J Exp Med. 2014 Jun 30;211(7):1363-77
pubmed: 24935257
Front Immunol. 2019 Jun 24;10:1392
pubmed: 31293573
Nat Rev Clin Oncol. 2017 Nov;14(11):655-668
pubmed: 28653677
PLoS One. 2011;6(6):e20702
pubmed: 21695190
Eur J Immunol. 2009 Oct;39(10):2648-56
pubmed: 19728312
Oncoimmunology. 2017 Nov 27;7(3):e1398877
pubmed: 29399402
Nat Rev Immunol. 2005 Jun;5(6):485-96
pubmed: 15928680
PLoS Biol. 2013 Jul;11(7):e1001610
pubmed: 23874157
Immunol Rev. 2012 Nov;250(1):167-79
pubmed: 23046129
FEBS Lett. 2006 Oct 9;580(23):5580-7
pubmed: 16949584
Ann Oncol. 2017 Dec 1;28(suppl_12):xii18-xii32
pubmed: 29045511
Cancer Res. 2001 Jul 1;61(13):5132-6
pubmed: 11431351
Clin Immunol. 2013 Oct;149(1):55-64
pubmed: 23891738
Front Immunol. 2018 Jun 15;9:1395
pubmed: 29963061
Pediatr Hematol Oncol. 2019 Feb;36(1):17-27
pubmed: 30870043
Immunity. 2014 Oct 16;41(4):543-54
pubmed: 25367571
J Exp Med. 2007 May 14;204(5):1131-44
pubmed: 17485514
Anticancer Res. 2018 Jul;38(7):4233-4239
pubmed: 29970556
Oncoimmunology. 2015 Apr 2;4(9):e1019981
pubmed: 26405592
Immunity. 2018 Mar 20;48(3):453-473
pubmed: 29562195
J Exp Med. 2004 May 3;199(9):1213-21
pubmed: 15123743
Cell Immunol. 2019 Sep;343:103753
pubmed: 29395859
Front Immunol. 2017 Nov 01;8:1386
pubmed: 29163475
J Lipid Res. 2019 Nov;60(11):1892-1904
pubmed: 31484693
Front Immunol. 2017 Sep 22;8:1178
pubmed: 29018445
J Clin Oncol. 2003 Feb 1;21(3):530-5
pubmed: 12560445
Oncoimmunology. 2015 Apr 02;4(3):e990800
pubmed: 25949908
Eur J Immunol. 2012 Sep;42(9):2505-10
pubmed: 22829134
J Transl Med. 2018 Jan 10;16(1):3
pubmed: 29316940